140 related articles for article (PubMed ID: 24926557)
21. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.
Chiu CH; Yang CT; Shih JY; Huang MS; Su WC; Lai RS; Wang CC; Hsiao SH; Lin YC; Ho CL; Hsia TC; Wu MF; Lai CL; Lee KY; Lin CB; Yu-Wung Yeh D; Chuang CY; Chang FK; Tsai CM; Perng RP; Chih-Hsin Yang J
J Thorac Oncol; 2015 May; 10(5):793-799. PubMed ID: 25668120
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor receptor mutations in synchronous recurrent lung cancer in an 82-year-old woman. A case story.
Kristiansen C; Olsen KE; Hansen NC; Hansen KH; Hansen O
Acta Oncol; 2012 Sep; 51(7):948-9. PubMed ID: 22471746
[No Abstract] [Full Text] [Related]
23. Lung adenocarcinoma patient with EGFR 19 exon insert mutation and its response to icotinib.
Zhu YC; Du KQ; Wang WX; Song ZB; Xu CW; Chen G; Zhuang W; Lv TF; Song Y
Lung Cancer; 2018 Jul; 121():101-104. PubMed ID: 29773459
[No Abstract] [Full Text] [Related]
24. Experience with erlotinib in lung adenocarcinoma harboring a coexisting KIF5B-RET fusion gene and EGFR mutation: report of a rare case.
Hirai F; Takenoyama M; Taguchi K; Toyozawa R; Inamasu E; Toyokawa G; Yoshida T; Shiraishi Y; Takenaka T; Yamaguchi M; Ushijima C; Seto T; Takeo S; Ichinose Y
J Thorac Oncol; 2014 May; 9(5):e37-9. PubMed ID: 24722163
[No Abstract] [Full Text] [Related]
25. Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: a case report.
Bordi P; Tiseo M; Bortesi B; Naldi N; Buti S; Ardizzoni A
Tumori; 2014; 100(1):e20-3. PubMed ID: 24675505
[TBL] [Abstract][Full Text] [Related]
26. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
[TBL] [Abstract][Full Text] [Related]
27. Promising Effects of Afatinib on Leptomeningeal Carcinomatosis Derived from Erlotinib-resistant Lung Adenocarcinoma.
Sekine A; Kato T; Iwasawa T; Baba T; Suido A; Sakuranaka H; Futaki M; Ogura T
Intern Med; 2016; 55(17):2457-61. PubMed ID: 27580550
[TBL] [Abstract][Full Text] [Related]
28. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
Costa DB; Nguyen KS; Cho BC; Sequist LV; Jackman DM; Riely GJ; Yeap BY; Halmos B; Kim JH; Jänne PA; Huberman MS; Pao W; Tenen DG; Kobayashi S
Clin Cancer Res; 2008 Nov; 14(21):7060-7. PubMed ID: 18981003
[TBL] [Abstract][Full Text] [Related]
29. Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma.
Tseng JS; Wang CL; Huang MS; Chen CY; Chang CY; Yang TY; Tsai CR; Chen KC; Hsu KH; Tsai MH; Yu SL; Su KY; Wu CW; Yang CT; Chen YM; Chang GC
PLoS One; 2014; 9(9):e107160. PubMed ID: 25215536
[TBL] [Abstract][Full Text] [Related]
30. Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).
Cardona AF; Arrieta O; Zapata MI; Rojas L; Wills B; Reguart N; Karachaliou N; Carranza H; Vargas C; Otero J; Archila P; Martín C; Corrales L; Cuello M; Ortiz C; Pino LE; Rosell R; Zatarain-Barrón ZL;
Target Oncol; 2017 Aug; 12(4):513-523. PubMed ID: 28620690
[TBL] [Abstract][Full Text] [Related]
31. Can EGFR mutation status be reliably determined in pre-operative needle biopsies from adenocarcinomas of the lung?
Lindahl KH; Sørensen FB; Jonstrup SP; Olsen KE; Loeschke S
APMIS; 2015 Apr; 123(4):289-97. PubMed ID: 25556929
[TBL] [Abstract][Full Text] [Related]
32. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
[TBL] [Abstract][Full Text] [Related]
33. EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy.
Guo H; Wan Y; Tian G; Liu Q; Kang Y; Li Y; Yao Z; Lin D
Oncol Rep; 2012 Mar; 27(3):880-90. PubMed ID: 22134479
[TBL] [Abstract][Full Text] [Related]
34. Complete pathologic response in lung tumors in two patients with metastatic non-small cell lung cancer treated with erlotinib.
Weber B; Sorensen BS; Knap MM; Madsen HH; Nexo E; Meldgaard P
J Thorac Oncol; 2011 Nov; 6(11):1946-9. PubMed ID: 22005472
[TBL] [Abstract][Full Text] [Related]
35. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
Qu G; Liu C; Sun B; Zhou C; Zhang Z; Wang P
Oncol Rep; 2014 Jul; 32(1):341-7. PubMed ID: 24842595
[TBL] [Abstract][Full Text] [Related]
36. Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.
Ji Y; Schwartz J; Hartford A; Ramsey J; Phillips J; Verschraegen C
JAMA Oncol; 2015 Sep; 1(6):838-40. PubMed ID: 26181671
[No Abstract] [Full Text] [Related]
37. Prognostic significance of microRNA expression in completely resected lung adenocarcinoma and the associated response to erlotinib.
Yan G; Yao R; Tang D; Qiu T; Shen Y; Jiao W; Ge N; Xuan Y; Wang Y
Med Oncol; 2014 Oct; 31(10):203. PubMed ID: 25192889
[TBL] [Abstract][Full Text] [Related]
38. Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients.
Pan JB; Hou YH; Zhang GJ
Asian Pac J Cancer Prev; 2013; 14(2):695-700. PubMed ID: 23621221
[TBL] [Abstract][Full Text] [Related]
39. Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?
Drpa G; Sreter KB; Manojlovic S; Kukulj S
Anticancer Drugs; 2018 Mar; 29(3):281-285. PubMed ID: 29280916
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study.
Boldrini L; Alì G; Gisfredi S; Ursino S; Baldini E; Melfi F; Lucchi M; Comin CE; Maddau C; Tibaldi C; Camacci T; Servadio A; Mussi A; Fontanini G
Oncol Rep; 2009 Oct; 22(4):683-91. PubMed ID: 19724844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
